interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Mometasone Furoate; Olopatadine Hydrochloride

Generic competition · all medicines · read 12 November 2026

Is there a generic of Mometasone Furoate; Olopatadine Hydrochloride, and who makes it?

Mometasone Furoate; Olopatadine Hydrochloride appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Mometasone Furoate; Olopatadine Hydrochloride1 dosage-form group in the Orange Book
0generic makers listed
  1. Mometasone Furoate; Olopatadine Hydrochloride appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Spray, Metered, Nasal

Brand listed, no generic listed as marketed

Brand listed as marketed: Ryaltris. No generic is listed as marketed.

20202025203020352040204501brand 2022data datePatent 10765686 listed to expire 4 September 2034Patent 10758550 listed to expire 4 September 2034Patent 10646500 listed to expire 4 September 2034Patent 10548907 listed to expire 4 September 2034Patent 11400101 listed to expire 4 September 2034Patent 12064442 listed to expire 4 September 2034Patent 10016443 listed to expire 4 September 2034Patent 10517880 listed to expire 4 September 2034Patent 9750754 listed to expire 4 September 2034Patent 9078923 listed to expire 4 September 2034Patent 10561672 listed to expire 4 September 2034Patent 9370483 listed to expire 4 September 2034Patent 10376526 listed to expire 4 September 2034Patent 9937189 listed to expire 4 September 2034Patent 11679210 listed to expire 3 September 2038Patent 12303635 listed to expire 8 April 2039Patent 12653833 listed to expire 21 November 2044Exclusivity NPP to 7 July 2029
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 7 July 2029Exclusivity NPP Ryaltris
  • 4 September 2034Patent 10765686
  • 4 September 2034Patent 10758550
  • 4 September 2034Patent 10646500
  • 4 September 2034Patent 10548907
  • 4 September 2034Patent 11400101
  • 4 September 2034Patent 12064442
  • 4 September 2034Patent 10016443
  • 4 September 2034Patent 10517880 drug product

9 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.